HC Wainwright & Co. Reiterates Buy on Jasper Therapeutics, Maintains $65 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Emily Bodnar has reiterated a Buy rating on Jasper Therapeutics (NASDAQ:JSPR) and maintained a $65 price target.
August 05, 2024 | 10:45 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Emily Bodnar has reiterated a Buy rating on Jasper Therapeutics and maintained a $65 price target.
The reiteration of a Buy rating and a high price target of $65 by a reputable analyst can boost investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100